The Walden Group, Inc.

The Walden Group, Inc. The Walden Group is a strategic merger & acquisition advisory firm specializing in the healthcare industry. About Us:

Healthcare Expertise and Experience.

With a 20-year proven track record, The Walden Group has served the healthcare industry as a specialized investment banking and consulting firm. We focus on the strategic interests of medical device, diagnostic, healthcare IT, medical services, distribution, specialized pharmaceutical, dental and other healthcare companies. Wall Street M&A Expertise Combined with Hands-on Strategic Healhcare Consu

lting. We offer sophisticated M&A and other investment banking services like a "bulge bracket" firm, but without an assembly-line process. We also provide pragmatic strategic consulting services by principals who have healthcare executive experience at major firms. Our close-to-operations perspective provides critical texture to our M&A work, and our transactional experience infuses a real-world practicality to our consulting work. Worldwide Network of Relationships. As healthcare industry experts, we hit the ground running and build-on ongoing relationships with major operating companies and financial sponsors. These relationships have been honed during the many transactions, trade show appearances and speaking engagements we conduct every year. In addition, more than 5,000 individuals around the world receive our Strategic Healthcare M&A Report on a quarterly basis. We are a known quantity worldwide. Rapid Deployment Force. With decades of healthcare industry expertise, we operate on a savvy, streamlined, client-focused basis. Without any "red tape", learning curve or need to develop relationships from scratch, The Walden Group can quickly and methodically execute fitted transactions and deliver value-added consulting projects

Research Driven. Our goal is to equip our clients with a thorough understanding of industry trends and challenges and provide effective solutions. We closely monitor mergers, acquisitions, strategic alliances and technology transfers within healthcare, as well as changes in government policies and regulations. We track product lines, distribution methods, strategic direction, and manufacturing capabilities of nearly 20,000 companies within our niche, from manufacturers, to distributors, to information technology companies, to service firms of all kinds. We monitor product lines at the customer-vendor level, noting medical specialties and subspecialties addressed. We record product line information in more than 650 such categories, enabling us to pinpoint, with extreme accuracy, strategic matches between companies, whether of a horizontal, vertical, diversification or investment nature.

The Walden Group is pleased to provide access to its 2025 Mid-Year Strategic Healthcare M&A Report which includes:- Sign...
07/21/2025

The Walden Group is pleased to provide access to its 2025 Mid-Year Strategic Healthcare M&A Report which includes:

- Significant M&A Deals by Sector - H1 2025
- Top Deals > $100m in Transaction Value Announced or Closed in H1 2025
- Performance of Leading Healthcare Companies
- Analysis of More Than 50 M&A Transactions

Visit https://lnkd.in/ehrVbRDn to download the report.

The Walden Group is pleased to provide access to its 2024 Q2 Strategic Healthcare M&A Report which includes:- Q2 2024 Ma...
08/21/2024

The Walden Group is pleased to provide access to its 2024 Q2 Strategic Healthcare M&A Report which includes:

- Q2 2024 Market Developments
- Noteworthy M&A Deals By Sector
- Top Deals > $100m in Transaction Value Announced or Closed in Q2 2024
- Performance of Leading Healthcare Companies
- Analysis of More Than 45 Q2 M&A Transactions

Click https://lnkd.in/eA44i8WA to download the Report.

The Walden Group is pleased to provide access to its 2024 Q1 Strategic Healthcare M&A Report which includes:-    Q1 2024...
05/15/2024

The Walden Group is pleased to provide access to its 2024 Q1 Strategic Healthcare M&A Report which includes:

- Q1 2024 Market Developments
- Noteworthy M&A Deals By Sector
- Top Deals > $100m in Transaction Value Announced or Closed in Q1 2024
- Performance of Leading Healthcare Companies
- Analysis of More Than 45 Q1 M&A Transactions

Click https://lnkd.in/eA44i8WA to download the Report.

The Walden Group is pleased to provide access to its 2023 Year-end Strategic Healthcare M&A Report which includes:- The ...
02/21/2024

The Walden Group is pleased to provide access to its 2023 Year-end Strategic Healthcare M&A Report which includes:

- The Big Picture -- 2023 and What to Expect in 2024
- Move-the-Needle M&A Deals by Sector - 2023 and YTD 2024
- Insights from the CEOs
- Top Deals > $100m in Transaction Value Announced or Closed in 2023
- Performance of Leading Healthcare Companies
- Analysis of More Than 60 Q4 M&A Transactions

Click https://lnkd.in/eVrFtJJ5 to download the Report.

The Walden Group is pleased to provide access to its 2024 Medical Device Outsourcing Developments report, which includes...
01/24/2024

The Walden Group is pleased to provide access to its 2024 Medical Device Outsourcing Developments report, which includes:

- Highlights from the 2024 JPM Healthcare Conference
- Key Outsourcing Trends
- Developments in Surgical Robotics, AI, 3D Printing and more.
- Notable CDMO and OEM Transactions
- And More

Visit https://lnkd.in/eeqKZ53J to download the Report.

The Walden Group is pleased to provide access to its Q3 2023 Strategic Healthcare M&A Report, which includes: - Q3 2023 ...
11/02/2023

The Walden Group is pleased to provide access to its Q3 2023 Strategic Healthcare M&A Report, which includes:

- Q3 2023 Market Overview
- Noteworthy M&A Deals By Sector
- Top Deals > $100m in Transaction Value Announced or Closed in Q3 2023
- Performance of Leading Healthcare Companies
- Analysis of More Than 45 Q3 M&A Transactions

Visit https://www.waldenmed.com/strategic-health-ma-report/ to download the Report.

The Walden Group is pleased to provide access to its Q2 2023 Strategic Healthcare M&A Report, which includes: - Q2 2023 ...
08/10/2023

The Walden Group is pleased to provide access to its Q2 2023 Strategic Healthcare M&A Report, which includes:

- Q2 2023 Market Overview
- Noteworthy M&A Deals By Sector
- Top Deals > $100m in Transaction Value Announced or Closed in Q2 2023
- Performance of Leading Healthcare Companies
- Analysis of More Than 45 Q2 M&A Transactions

Visit https://www.waldenmed.com/strategic-health-ma-report/ to download the Report.

The Walden Group is pleased to provide access to its Q1 2023 Strategic Healthcare M&A Report, which includes: - Q1 2023 ...
05/02/2023

The Walden Group is pleased to provide access to its Q1 2023 Strategic Healthcare M&A Report, which includes:

- Q1 2023 Market Overview
- Noteworthy M&A Deals By Sector
- Top Deals > $100m in Transaction Value Announced or Closed in Q1 2023
- Performance of Leading Healthcare Companies
- Analysis of More Than 45 Q1 M&A Transactions

Visit https://lnkd.in/eA44i8WA to download the Report.

Werfen Group Buys Immucor for $2bSpain-based manufacturer and distributor of diagnostic instruments Werfen has acquired ...
03/29/2023

Werfen Group Buys Immucor for $2b

Spain-based manufacturer and distributor of diagnostic instruments Werfen has acquired Immucor, a manufacturer of transfusion and transplant diagnostic devices. The acquisition adds platelet detection, diagnostic analyzers, blood monitoring and molecular testing products that help match patients and donors. Deal terms -- $2b.



https://www.waldenmed.com/blog-post/werfen-group-buys-immucor-for-2b/

The Walden Group is pleased to provide access to its Q4 2022 Strategic Healthcare M&A Report, which includes:     - Rece...
03/10/2023

The Walden Group is pleased to provide access to its Q4 2022 Strategic Healthcare M&A Report, which includes:

- Recent Divestitures and Spin-Offs
- Diagnostic and Medical Device Deals with Valuations over $100m
- Noteworthy M&A Deals By Sector
- Top Deals > $100m in Transaction Value Announced or Closed in 2022
- Performance of Leading Healthcare Companies
- Analysis of More Than 45 Q4 M&A Transactions

Download here: https://www.waldenmed.com/strategic-health-ma-report/

Shockwave Medical to Acquire Neovasc for $100mShockwave Medical, a $237m developer of technologies treating calcified pl...
02/07/2023

Shockwave Medical to Acquire Neovasc for $100m

Shockwave Medical, a $237m developer of technologies treating calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve disease, is acquiring Neovasc, a $2.5m Canada-based developer of transcatheter devices treating refractory angina and mitral valve disease.

https://www.waldenmed.com/blog-post/shockwave-medical-to-acquire-neovasc-for-100m/

Address

560 White Plains Road
Tarrytown, NY
10591

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm
Saturday 9am - 11pm
Sunday 12am - 11pm

Alerts

Be the first to know and let us send you an email when The Walden Group, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share